Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HUTONG: Port Delivery System With Ranibizumab in Chinese Patients With nAMD
NCT05562947Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Jun 2024
- Primary completion
- Jun 2027
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ranibizumab in neovascular age-related macular degeneration (NVAMD), sponsored by Roche. Started Jun 2024; status: active, not recruiting.
02
Drugs
ranibizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT05562947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05562947.